Advertisement

Topics

723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover

2014-07-23 21:13:25 | BioPortfolio

Summary

This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Allergic Rhinitis

Intervention

placebo, GSK835726 10mg, GSK1004723 1000mcg, Cetirizine 10mg

Location

GSK Investigational Site
Hannover
Niedersachsen
Germany
30625

Status

Completed

Source

GlaxoSmithKline

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:13:25-0400

Clinical Trials [945 Associated Clinical Trials listed on BioPortfolio]

Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the e...

Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an allergen...

A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic inflammation. The study will investigate the paradigm of multiple receptor antagonism in aller...

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

This study is an open-label, randomized, fasted, single-dose, 2-way crossover study to compare the pharmacokinetic characteristics and safety between CKD-380 10mg and D308 10mg in healthy ...

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions

An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. ...

PubMed Articles [1535 Associated PubMed Articles listed on BioPortfolio]

Cetirizine and thalidomide synergistically inhibit mammary tumorigenesis and angiogenesis in 7,12-dimethylbenz(a)anthracene-treated rats.

Cetirizine (CET) and thalidomide (THA) have been previously found to influence angiogenesis. The present study aimed to assess the ability of these drugs to influence mammary carcinogenesis in rats.

Cryosurgery in the treatment of allergic and non-allergic rhinitis.

Introduction: Pharmacological treatment of both allergic and non-allergic rhinitis is not always effective. The aim: Assessment of the effectiveness of treatment of patients with allergic and non-alle...

SUBSTITUTION THERAPY WITH AMPHETAMINE-ISOTHERAPIC ATTENUATES AMPHETAMINE TOXICOLOGICAL ASPECTS OF ADDICTION.

amphetamine (AMPH) is related to development of addiction, anxiety-like behaviors and impairments of memory after chronic use. In the current experiment, an ultra-high dilution (10mg/mL) of AMPH was u...

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

To prevent the global health burdens of human immunodeficiency virus [HIV] and unintended/mistimed pregnancies, we developed an intravaginal ring [IVR] that delivers tenofovir [TFV] at ~10mg/day alone...

Efficacy, safety, and quality of life in a multi-center, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in peanut allergic children.

Only two, small placebo-controlled trials on peanut- oral immunotherapy (OIT) have been published.

Medical and Biotech [MESH] Definitions

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.

Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects.

More From BioPortfolio on "723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial